VPS9 Antibody

What is the VPS9 domain and why is it significant in cellular research?

The VPS9 domain is a conserved protein domain approximately 140 residues in length that functions as a catalytic core for guanine nucleotide exchange on Rab5 GTPases or their yeast homologue VPS21. Structurally, the VPS9 domain adopts a layered fold of six alpha helices, with conserved residues from the fourth and sixth helices and their N-terminal loops forming the interaction surface with Rab5 and Rab21 . This domain plays a critical role in endosomal trafficking by facilitating the conversion of Rab5 from GDP-bound to GTP-bound states, thereby activating this essential regulator of endocytosis and endosome biogenesis. VPS9-containing proteins are crucial for proper cellular vesicle trafficking and organelle formation, making them important targets for cellular biology research .

How do VPS9 antibodies differ from antibodies against other domains in experimental applications?

VPS9 antibodies are specifically designed to recognize and bind to either the VPS9 domain itself or proteins containing this domain, enabling researchers to study proteins involved in endosomal trafficking with high specificity. Unlike antibodies against more common domains, VPS9 antibodies require careful validation due to the domain's specific structural characteristics and the potential for cross-reactivity with other GEF-containing proteins. When designing experiments, researchers should consider that VPS9 domain proteins often exhibit dynamic subcellular localization patterns, shifting between cytosolic and membrane-bound states depending on their activation status, which can affect epitope accessibility. Additionally, since the VPS9 domain interacts specifically with Rab5 in its GDP-bound and nucleotide-free forms , antibodies targeting this domain may potentially interfere with protein-protein interactions, necessitating careful experimental design and interpretation.

What are the recommended applications for VPS9 antibodies in research?

VPS9 antibodies can be effectively employed in multiple research applications, each with specific methodological considerations:

• Western Blotting: Useful for detecting expression levels of VPS9-containing proteins under different experimental conditions. Typical dilutions range from 1:500 to 1:2000, with optimization recommended for each specific antibody .

• Immunohistochemistry: Can localize VPS9-domain proteins in tissue sections, typically using paraffin-embedded samples at dilutions around 1:100, as demonstrated with related vesicular trafficking proteins .

• Immunocytochemistry/Immunofluorescence: Valuable for examining subcellular localization patterns of VPS9 proteins, particularly in relation to endosomal compartments, using dilutions around 1:100 .

• Co-immunoprecipitation: Essential for studying protein interactions, particularly with Rab5 GTPases, allowing researchers to confirm the binding specificity between VPS9-domain proteins and their targets .

• Functional assays: Can be used in GEF activity assays to measure nucleotide exchange on Rab5, particularly when combined with recombinant proteins and fluorescence-based assays .

What controls are essential when validating VPS9 antibodies for research applications?

Rigorous validation of VPS9 antibodies requires multiple controls to ensure specificity and reliability:

• Positive Controls: Lysates from tissues or cell lines known to express the target VPS9 protein, such as liver tissue extracts or A549 cells for human samples .

• Negative Controls:

  • Tissues/cells with confirmed absence of target expression

  • Samples from knockout models (e.g., VPS9a T-DNA insertion mutants in Arabidopsis)

  • Pre-absorption with immunizing peptide/recombinant protein

• Antibody Specificity Controls:

  • Western blotting to confirm single band of expected molecular weight

  • Parallel testing with different antibodies targeting separate epitopes of the same protein

  • Testing reactivity against recombinant VPS9 domain proteins and related family members to assess cross-reactivity

• Application-Specific Controls:

  • For immunofluorescence: Secondary antibody-only controls

  • For IP experiments: IgG isotype controls

  • For functional assays: Heat-inactivated antibody controls

• Cross-Species Validation: If using the antibody across different species, confirm specificity in each species separately due to potential epitope variations.

How can researchers effectively troubleshoot non-specific binding when using VPS9 antibodies?

When encountering non-specific binding with VPS9 antibodies, implement the following troubleshooting methodology:

Step 1: Optimize blocking conditions

• Test different blocking agents (BSA, milk, normal serum, commercial blockers)

• Increase blocking time (from 1 hour to overnight)

• Adjust blocker concentration (typically 3-5% for most applications)

Step 2: Modify antibody conditions

• Titrate antibody concentration (perform dilution series)

• Increase washing duration and frequency between steps

• Incubate primary antibody at 4°C overnight instead of at room temperature

• Pre-absorb antibody with recombinant VPS9 domain to reduce non-specific binding

Step 3: Adjust sample preparation

• Optimize fixation protocol (test different fixatives and durations)

• Include detergents in wash buffers (0.1-0.3% Triton X-100 or Tween-20)

• For tissue samples, test antigen retrieval methods (heat-induced vs. enzymatic)

Step 4: Implement additional controls

• Compare results with knockout/knockdown samples

• Use peptide competition assays to confirm specificity

• Test alternative VPS9 antibodies targeting different epitopes

Step 5: Consider sample-specific issues

• For highly expressing tissues, reduce antibody concentration further

• For low-expressing samples, consider signal amplification methods (e.g., TSA)

• Evaluate potential post-translational modifications that might affect epitope recognition

What are the optimal conditions for preserving VPS9 epitopes during sample preparation?

Preserving VPS9 epitopes requires careful attention to sample preparation methodology:

For Cell Lysates (Western Blotting):

• Lyse cells in buffer containing 50mM Tris-HCl (pH 7.4), 150mM NaCl, 1% NP-40 or Triton X-100

• Include protease inhibitor cocktail and phosphatase inhibitors

• Maintain samples at 4°C throughout processing

• Add reducing agents (e.g., DTT or β-mercaptoethanol) immediately before gel loading

• Avoid repeated freeze-thaw cycles of prepared samples

For Tissue Fixation (IHC/ICC):

• For paraffin embedding: Fix tissues in 10% neutral-buffered formalin for 24-48 hours

• For frozen sections: Fix briefly in 4% paraformaldehyde (10-15 minutes)

• For cultured cells: Fix in 4% paraformaldehyde for 10-15 minutes at room temperature

• Consider epitope mapping data when selecting fixation methods, as some VPS9 epitopes may be fixation-sensitive

Antigen Retrieval Methods:

• Heat-induced epitope retrieval: 10mM citrate buffer (pH 6.0) at 95-100°C for 20 minutes

• Alternative: Tris-EDTA buffer (pH 9.0) for certain antibodies

• Allow slow cooling to room temperature for optimal epitope exposure

• For challenging samples, test enzymatic retrieval with proteinase K (1-5 μg/ml for 5-15 minutes)

Storage Considerations:

• Store fixed slides at -20°C if not processed immediately

• Process tissue samples within 6 months of fixation for optimal results

• For long-term storage of lysates, aliquot and maintain at -80°C

How can VPS9 antibodies be used to study the interaction between VPS9 and Rab5 GTPases?

VPS9 antibodies can elucidate the critical interaction between VPS9-domain proteins and Rab5 GTPases through several methodological approaches:

Co-Immunoprecipitation Protocol:

• Prepare cell lysates in mild lysis buffer (25mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 5% glycerol) with protease inhibitors

• Pre-clear lysates with Protein A/G beads for 1 hour at 4°C

• Incubate cleared lysates with VPS9 antibody overnight at 4°C with gentle rotation

• Add Protein A/G beads and incubate for 2-4 hours at 4°C

• Wash beads 4-5 times with lysis buffer

• Elute proteins and analyze by Western blotting for Rab5

• Critical control: Use nucleotide-state specific Rab5 mutants (GDP-fixed S24N and nucleotide-free N123I) as VPS9 domain proteins interact preferentially with these forms

Proximity Ligation Assay (PLA):

• Fix cells with 4% paraformaldehyde for 15 minutes

• Permeabilize with 0.1% Triton X-100 for 10 minutes

• Block with 5% BSA for 1 hour

• Incubate with primary antibodies against VPS9 and Rab5

• Perform PLA according to manufacturer's protocol

• Counterstain for endosomal markers (EEA1) to confirm localization

• Analyze interaction spots by confocal microscopy

FRET Analysis:

• Transfect cells with fluorescently tagged VPS9 and Rab5 constructs

• Fix and stain with VPS9 antibodies conjugated to acceptor fluorophores

• Perform acceptor photobleaching FRET analysis

• Calculate FRET efficiency to quantify protein proximity

• Compare wild-type Rab5 with nucleotide-binding mutants to confirm specificity

Nucleotide Exchange Assays:

• Express and purify recombinant VPS9 domain and Rab5

• Measure nucleotide exchange by monitoring intrinsic Trp fluorescence

• Test whether pre-incubation with VPS9 antibodies affects exchange activity

• Compare activity across different Rab GTPases to confirm specificity

What are the best approaches for using VPS9 antibodies to investigate endosomal trafficking defects?

Investigating endosomal trafficking defects with VPS9 antibodies requires multilayered experimental approaches:

Quantitative Immunofluorescence Protocol:

• Culture cells under experimental conditions (e.g., drug treatment, gene knockdown)

• Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

• Permeabilize with 0.1% Triton X-100 for 10 minutes

• Block with 5% normal serum for 1 hour

• Co-stain with antibodies against:

  • VPS9-domain protein

  • Endosomal markers (EEA1, Rab5, Rab7)

  • Cargo proteins of interest

• Image using confocal microscopy with identical acquisition settings

• Quantify:

  • Colocalization coefficients between VPS9 and endosomal markers

  • Endosome size and number

  • Intracellular distribution of endosomes

• Compare results between control and experimental conditions

Live-Cell Imaging Methodology:

• Express fluorescently-tagged endocytic cargo (e.g., transferrin receptor)

• Perform pulse-chase experiments with fluorescently-labeled ligands

• Track cargo internalization and movement through endocytic compartments

• Compare trafficking kinetics between control and VPS9-deficient cells

• Correlate with fixed-cell VPS9 antibody staining patterns

Biochemical Fractionation Approach:

• Homogenize cells in isotonic buffer

• Perform differential centrifugation to isolate endosomal fractions

• Analyze fractions by Western blotting using VPS9 antibodies

• Quantify changes in VPS9 protein distribution across fractions

• Correlate with markers of different endosomal compartments

Electron Microscopy with Immunogold Labeling:

• Fix cells with 4% paraformaldehyde/0.1% glutaraldehyde

• Process for ultrathin sectioning

• Perform immunogold labeling with VPS9 antibodies

• Examine endosome morphology and VPS9 localization at ultrastructural level

• Quantify changes in endosome number, size, and morphology

How can researchers use VPS9 antibodies to study its role in development and disease models?

VPS9 antibodies can be valuable tools for investigating developmental processes and disease mechanisms:

Developmental Studies Protocol:

• Collect tissue samples from different developmental stages

• Process for immunohistochemistry or prepare lysates for Western blotting

• Use VPS9 antibodies to track expression patterns throughout development

• Correlate with developmental phenotypes in VPS9-deficient models

• Quantitative analysis:

Disease Model Applications:

• Compare VPS9 protein expression and localization between normal and pathological tissues

• Perform Western blot analysis with densitometric quantification

• Conduct immunohistochemistry to assess tissue distribution patterns

• Correlate findings with disease progression markers

• For neurodegenerative diseases, examine colocalization with protein aggregates

• In cancer models, assess relationship to invasive/metastatic potential

Functional Rescue Experiments:

• In VPS9-deficient models showing developmental defects :

  • Introduce wild-type or mutant VPS9 constructs

  • Assess rescue of phenotypes using morphological and functional readouts

  • Use VPS9 antibodies to confirm appropriate expression and localization

• Document rescue outcomes quantitatively:

How should researchers interpret discrepancies in VPS9 antibody results across different experimental techniques?

When encountering discrepancies between different experimental approaches using VPS9 antibodies, implement this systematic analysis framework:

Step 1: Technical Validation

• Verify antibody quality through Western blot analysis

• Check for batch-to-batch variations by requesting antibody validation data

• Confirm epitope accessibility in different applications (proteins denatured in WB vs. native in IP)

• Evaluate fixation effects on epitope recognition for microscopy applications

Step 2: Comparative Analysis

• Document discrepancies in a structured format:

Step 3: Biological Interpretation

• Consider that VPS9-domain proteins may exist in multiple conformational states

• Evaluate potential post-translational modifications affecting epitope recognition

• Assess the impact of nucleotide-binding status on antibody accessibility

• Examine protein complex formation that might mask epitopes

Step 4: Resolution Strategies

• Use multiple antibodies targeting different epitopes of the same protein

• Implement complementary detection methods (e.g., epitope tagging)

• Perform domain-specific functional assays (e.g., GEF activity measurements)

• Correlate with orthogonal approaches (mass spectrometry, CRISPR/Cas9 editing)

What are the optimal protocols for studying VPS9's role in protein processing and trafficking using antibodies?

To investigate VPS9's critical role in protein processing and trafficking, researchers can implement these specialized protocols:

Pulse-Chase Analysis Protocol:

• Metabolically label cells with 35S-methionine/cysteine for 15-20 minutes

• Chase with unlabeled medium for various time points (0-4 hours)

• Immunoprecipitate cargo proteins of interest

• Analyze by SDS-PAGE and autoradiography

• Compare processing kinetics between control and VPS9-deficient cells

• Expected outcome: VPS9-deficient cells may show delayed processing of proteins like ROP4, with higher levels of unprocessed precursors

Subcellular Fractionation with Immunoblotting:

• Prepare cell homogenates in isotonic buffer

• Separate organelles by differential centrifugation

• Isolate membrane fractions using sucrose gradient ultracentrifugation

• Analyze fractions by immunoblotting with:

  • VPS9 antibodies

  • Markers for different compartments (ER, Golgi, endosomes)

  • Cargo protein antibodies

• Quantify protein distribution across fractions

• Compare results between normal and VPS9-deficient cells

Vesicular Trafficking Visualization:

• Transfect cells with fluorescently-tagged cargo proteins

• Allow internalization and trafficking for various time periods

• Fix cells and immunostain for VPS9 and compartment markers

• Acquire 3D confocal z-stacks

• Perform quantitative colocalization analysis

• Track vesicle movements in live-cell imaging experiments

• Compare trafficking patterns between control and experimental conditions

• Predicted phenotype: VPS9-deficient cells may show accumulation of novel vesicles and disturbed secretion patterns

Cargo Processing Analysis:

• Prepare cell lysates from control and VPS9-deficient cells

• Perform Western blotting for cargo proteins that undergo processing

• Quantify the ratio of precursor to mature forms

• Compare processing efficiency under different conditions

• Expected result: VPS9-deficient cells may show 2-4 fold higher levels of unprocessed precursor proteins

What emerging technologies can be combined with VPS9 antibodies to advance research in this field?

Several cutting-edge technologies can be integrated with VPS9 antibody-based approaches to advance understanding of vesicular trafficking:

Super-Resolution Microscopy Applications:

• STORM/PALM imaging:

  • Label VPS9 with photoconvertible fluorophore-conjugated antibodies

  • Achieve 20-30nm resolution of endosomal structures

  • Map precise organization of VPS9 relative to Rab5 on endosomal membranes

  • Correlate with functional studies of GEF activity

• Expansion Microscopy:

  • Physically expand specimens 4-10x using swellable polymer

  • Immunostain for VPS9 and endosomal markers

  • Resolve subendosomal domains previously undetectable by conventional microscopy

CRISPR-Based Approaches:

• Endogenous Tagging:

  • Insert fluorescent protein tags at endogenous VPS9 loci

  • Validate localization patterns with VPS9 antibodies

  • Track dynamics without overexpression artifacts

• CRISPRi/CRISPRa:

  • Modulate VPS9 expression levels without complete knockout

  • Create dosage series to determine threshold requirements

  • Assess phenotypic consequences using antibody-based detection

Quantitative Proteomics Integration:

• Proximity-Based Labeling:

  • Express VPS9 fused to BioID or APEX2

  • Identify proximal proteins in living cells

  • Validate interactions using co-IP with VPS9 antibodies

  • Map the dynamic VPS9 interactome under different conditions

• Antibody-Based Proteomics:

  • Immunoprecipitate VPS9 complexes under various cellular conditions

  • Identify interaction partners by mass spectrometry

  • Construct condition-specific interaction networks

  • Compare to predicted Rab5-dependent interactions

Organoid and In Vivo Applications:

• Advanced Tissue Clearing:

  • Apply CLARITY or iDISCO clearing methods to tissues or organoids

  • Perform whole-mount immunostaining with VPS9 antibodies

  • Image entire structures with light-sheet microscopy

  • Create 3D maps of VPS9 distribution in complex tissues

• Intravital Microscopy:

  • Inject fluorescently-labeled VPS9 antibody fragments

  • Track dynamics in living tissues

  • Correlate with physiological or pathological processes

How do antibodies against different VPS9-domain proteins compare in research applications?

Researchers should consider the following comparative analysis when selecting antibodies against different VPS9-domain proteins:

Specificity Comparison:

Functional Domain Recognition:

Different antibodies may target distinct functional domains within VPS9 proteins, affecting their utility in specific applications:

• VPS9 Catalytic Domain Antibodies:

  • Ideal for studying GEF activity

  • May block interaction with Rab5

  • Useful for neutralization experiments

  • Located between residues ~140 in conserved domains

• N-Terminal Region Antibodies:

  • Useful for proteins with extended N-terminal domains (e.g., TgVps9)

  • Less likely to interfere with GEF activity

  • Better for immunoprecipitation studies

• C-Terminal Region Antibodies:

  • May detect protein-protein interaction domains

  • Less conserved across species

  • Potentially useful for species-specific detection

Application-Specific Performance:

What special considerations apply when using VPS9 antibodies in different model organisms?

Working with VPS9 antibodies across diverse model organisms requires tailored approaches:

Plant Models (e.g., Arabidopsis):

• Consider the presence of two distinct types of Rab5 in plants versus single type in animals

• Validate antibodies specifically for plant VPS9 proteins (e.g., VPS9a)

• Optimize tissue extraction protocols to account for cell wall components

• Use T-DNA insertion mutants as negative controls for antibody validation

• Expected phenotypes in VPS9-deficient plants include developmental abnormalities

Mammalian Systems:

• Consider potential cross-reactivity with multiple VPS9-domain proteins

• Validate across different tissues due to variable expression patterns

• Use appropriate lysis buffers to solubilize membrane-associated pools

• Consider potential post-translational modifications affecting epitope recognition

• Knockout/knockdown validation is essential for specificity confirmation

Parasite Models (e.g., T. gondii):

• Account for unique structural features of parasite VPS9 proteins (extended N-terminus)

• Consider specialized secretory organelles unique to parasites (rhoptries, micronemes)

• Use species-specific antibodies to avoid cross-reactivity with host proteins

• Validate in transgenic parasite lines with tagged or modified VPS9

• Expected phenotypes include defects in specialized secretory organelles and host cell invasion

Yeast Models:

• Consider evolutionary conservation of the VPS9 domain

• Validate antibody recognition of yeast VPS9 proteins

• Use yeast genetic tools (deletion strains) for validation

• Employ yeast two-hybrid systems to confirm antibody specificity for protein interactions

Tissue-Specific Considerations:

How can VPS9 antibodies contribute to understanding disease mechanisms?

VPS9 antibodies offer valuable tools for investigating disease pathogenesis through several methodological approaches:

Neurodegenerative Disease Applications:

• Compare VPS9 expression and localization in patient vs. control tissues

• Assess colocalization with disease-specific protein aggregates

• Quantify endosomal abnormalities using morphometric analysis

• Correlate with disease progression markers

• Monitor therapeutic responses in disease models

Analytical approach for Alzheimer's Disease samples:

• Perform triple-labeling with VPS9, Aβ, and endosomal markers

• Quantify enlarged endosome frequency in affected neurons

• Measure distance between VPS9-positive structures and amyloid deposits

• Compare VPS9 distribution in neurons with and without tangles

Cancer Research Applications:

• Analyze VPS9 expression patterns across tumor types and grades

• Correlate with markers of endosomal trafficking and receptor recycling

• Assess relationship to metastatic potential

• Monitor changes in response to targeted therapies

• Expected findings: Potential alterations in VPS9 localization or expression in certain cancer types, similar to observations in liver cancer tissue

Infectious Disease Research:

• Investigate pathogen manipulation of host VPS9 proteins

• Study VPS9 roles in pathogen entry and intracellular survival

• Assess VPS9 function in immune cell response to infection

• Example application: Tracking VPS9-dependent processes during T. gondii infection

• Quantitative analysis of pathogen-induced VPS9 relocalization

Therapeutic Development Applications:

• Use VPS9 antibodies to screen for compounds affecting endosomal trafficking

• Develop antibody-based imaging agents for trafficking disorders

• Explore antibody-drug conjugates targeting VPS9-expressing cells

• Validate therapeutic targets in the VPS9 pathway

What are the most promising computational approaches for enhancing VPS9 antibody research?

Computational methods can significantly enhance VPS9 antibody research through several advanced approaches:

Structural Biology Integration:

• Use homology modeling and molecular dynamics to predict VPS9 domain structures

• Map epitopes recognized by different antibodies onto 3D models

• Predict effects of mutations on epitope recognition

• Simulate VPS9-Rab5 interactions to identify critical interface residues

• Design improved antibodies with enhanced specificity for particular conformations

Machine Learning Applications:

• Develop algorithms to analyze VPS9 localization patterns in microscopy images

• Train neural networks to classify endosomal morphologies in VPS9-deficient cells

• Implement automated tracking of VPS9-positive vesicles in live-cell imaging

• Create predictive models for VPS9 interaction networks based on proteomic data

• Use natural language processing to mine literature for VPS9-related discoveries

Systems Biology Integration:

• Construct comprehensive models of VPS9-regulated trafficking networks

• Predict system-level consequences of VPS9 dysregulation

• Identify potential compensatory mechanisms in VPS9-deficient systems

• Model the dynamic behavior of VPS9-Rab5 signaling modules

• Integrate transcriptomic, proteomic, and imaging data for holistic understanding

Antibody Design Optimization:

• Apply computational tools to predict optimal epitopes for antibody generation

• Use structure-based design to enhance antibody specificity and affinity

• Model antibody-antigen interactions to minimize cross-reactivity

• Predict optimal humanization strategies for therapeutic applications

• Design antibodies that distinguish between different functional states of VPS9 proteins

By implementing these advanced computational approaches, researchers can significantly enhance the specificity, sensitivity, and applications of VPS9 antibodies in diverse experimental contexts.